Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma

References

1. 1.↵
   1. Norden AD,
   2. Drappatz J,
   3. Wen PY

   . Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5: 610–20

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Rahman R,
   2. Smith S,
   3. Rahman C,
   4. et al

   . Antiangiogenic therapy and mechanisms of tumor resistance in malignant glioma. J Oncol 2010; 2010: 251231. Epub 2010 Apr 11
3. 3.↵
   1. Fischer I,
   2. Gagner JP,
   3. Law M,
   4. et al

   . Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 2005; 15: 297–310

   PubMedWeb of Science
4. 4.↵
   1. Friedman HS,
   2. Prados MD,
   3. Wen PY,
   4. et al

   . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009; 27: 4733–40. Epub 2009 Aug 31

   Abstract/FREE Full Text
5. 5.↵
   1. Kreisl TN,
   2. Kim L,
   3. Moore K,
   4. et al

   . Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27: 740–45

   Abstract/FREE Full Text
6. 6.↵
   1. Lai A,
   2. Nghiemphu PL,
   3. Green RM,
   4. et al

   . Updated results of phase II trial of bevacizumab in combination with temozolomide and regional radiation therapy for upfront treatment of patients with newly-diagnosed glioblastoma multiforme. Neuro Oncol 2009; 11: 632
7. 7.↵
   1. Pope WB,
   2. Lai A,
   3. Nghiemphu P,
   4. et al

   . MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006; 66: 1258–60

   Abstract/FREE Full Text
8. 8.↵
   1. Wen PY,
   2. Macdonald DR,
   3. Reardon DA,
   4. et al

   . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: 1963–72. Epub 2010 Mar 15

   Abstract/FREE Full Text
9. 9.↵
   1. Clarke JL,
   2. Chang S

   . Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009; 9: 241–46

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Levin VA,
    2. Bidaut L,
    3. Hou P,
    4. et al

    . Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011; 79: 1487–95

    CrossRefPubMed
11. 11.↵
    1. Chamberlain MC

    . Pseudoprogression in glioblastoma. J Clin Oncol 2008; 26: 4359, author reply 4359–60

    FREE Full Text
12. 12.↵
    1. Claes A,
    2. Wesseling P,
    3. Jeuken J,
    4. et al

    . Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization. Mol Cancer Ther 2008; 7: 71–78

    Abstract/FREE Full Text
13. 13.↵
    1. Fukushima T,
    2. Takeshima H,
    3. Kataoka H

    . Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Anticancer Res 2009; 29: 4845–54

    Abstract/FREE Full Text
14. 14.↵
    1. Jung TY,
    2. Jung S,
    3. Moon KS,
    4. et al

    . Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 2010; 23: 1269–76

    PubMed
15. 15.↵
    1. Zhang J,
    2. Stevens MF,
    3. Laughton CA,
    4. et al

    . Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. Oncology 2010; 78: 103–14

    CrossRefPubMedWeb of Science
16. 16.↵
    1. Drabycz S,
    2. Roldan G,
    3. de Robles P,
    4. et al

    . An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage 2010; 49: 1398–405

    CrossRefPubMed
17. 17.↵
    1. Ellingson BM,
    2. Malkin MG,
    3. Rand SD,
    4. et al

    . Validation of functional diffusion maps (fDMs) as a biomarker for human glioma cellularity. J Magn Reson Imaging 2010; 31: 538–48

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Carlson MR,
    2. Pope WB,
    3. Horvath S,
    4. et al

    . Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res 2007; 13: 2592–98

    Abstract/FREE Full Text
19. 19.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J,
    4. et al

    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252: 182–89

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Higano S,
    2. Yun X,
    3. Kumabe T,
    4. et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006; 241: 839–46

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Oh J,
    2. Henry RG,
    3. Pirzkall A,
    4. et al

    . Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, and relative cerebral blood volume. J Magn Reson Imaging 2004; 19: 546–54

    CrossRefPubMed
22. 22.↵
    1. Otsu N

    . A threshold selection method from gray-level histograms. IEEE Trans Syst Man Cybern B Cybern 1979; 9: 62–66

    CrossRef
23. 23.↵
    1. Hegi ME,
    2. Diserens AC,
    3. Gorlia T,
    4. et al

    . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997–1003

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Macdonald DR,
    2. Cascino TL,
    3. Schold SC Jr.,
    4. et al

    . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8: 1277–80

    Abstract
25. 25.↵
    1. Brandes AA,
    2. Franceschi E,
    3. Tosoni A,
    4. et al

    . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008; 26: 2192–97

    Abstract/FREE Full Text
26. 26.↵
    1. Wong ET,
    2. Brem S

    . Antiangiogenesis treatment for glioblastoma multiforme: challenges and opportunities. J Natl Compr Canc Netw 2008; 6: 515–22

    Abstract/FREE Full Text
27. 27.↵
    1. Zhou Q,
    2. Guo P,
    3. Kruh GD,
    4. et al

    . Predicting human tumor drug concentrations from a preclinical pharmacokinetic model of temozolomide brain disposition. Clin Cancer Res 2007; 13: 4271–79

    Abstract/FREE Full Text
28. 28.↵
    1. Zeng QS,
    2. Li CF,
    3. Liu H,
    4. et al

    . Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys 2007; 68: 151–58

    CrossRefPubMed
29. 29.↵
    1. Minamikawa S,
    2. Kono K,
    3. Nakayama K,
    4. et al

    . Glucocorticoid treatment of brain tumor patients: changes of apparent diffusion coefficient values measured by MR diffusion imaging. Neuroradiology 2004; 46: 805–11

    CrossRefPubMedWeb of Science